TLS in Tumors May Predict Immunotherapy Benefit in NSCLC TLS in Tumors May Predict Immunotherapy Benefit in NSCLC
New data indicate that tertiary lymphoid structures could predict which patients with advanced non-small cell lung cancer will benefit most from immunotherapy.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer